Company news

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) news

Werewolf Therapeutics, Inc. news releases on 6ix. Latest, Jul 31, 2026: Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent…

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) news

Press releases & updates

Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Werewolf Therapeutics to Participate in the BIO International Convention

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors